Risk of kidney failure across proteinuria levels among patients with immunoglobulin A nephropathy and stable estimated glomerular filtration rate

Abstract Introduction Proteinuria is an established prognostic marker in immunoglobulin A nephropathy (IgAN). Its relevance among patients with stable estimated glomerular filtration rate (eGFR) is less well characterized. This study evaluated patients with stable eGFR to assess if cumulative time-averaged proteinuria (TA-P) is associated with subsequent kidney failure. Methods This retrospective cohort study used linked US claims from Komodo Research Data and electronic medical records (EMR) data from Norstella (2016–2026). Eligible patients were adults aged ≥ 18 years with IgAN identified through diagnosis codes or clinical notes, from claims or EMR. eGFR stability was defined as an annualized slope corresponding to a decline of < 1 mL/min/1.73 m² assessed over 24 (± 6) months. Multivariable Cox proportional hazards models estimated associations between TA-P thresholds and kidney failure, adjusting for demographics, baseline kidney function, comorbidities, hematuria, and treatment use. Results One thousand, two hundred twenty-three patients met the inclusion criteria including having stable eGFR for 2 years. Despite having stable eGFR, patients with TA- P ≥ 0.5 g/day had 1.55 times the hazard of kidney failure compared with patients with TA- P < 0.5 g/day (HR, 1.55; 95% CI, 1.07–2.23; p = 0.019). A similar finding was demonstrated for patients with TA- P ≥ 0.3 g/day versus TA- P < 0.3 g/day (HR, 1.80; 95% CI, 1.21–2.67; p = 0.004). Consistent results were observed across sensitivity analyses including a 1-year stability period. Conclusions Among patients with IgAN and stable eGFR over a 24-month period, achieving the KDIGO-recommended proteinuria targets (< 0.5 g/day, preferably < 0.3 g/day) remains clinically important even when kidney function appears stable.

Authors

Institutions

Publication Details

Journal
Rare Kidney Diseases
Published
2026-10-29
DOI
https://doi.org/10.1007/s44531-026-00015-1
Primary Topic
Renal Diseases and Glomerulopathies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Risk of kidney failure across proteinuria levels among patients with immunoglobulin A nephropathy and stable estimated glomerular filtration rate

Manish R. Maski, Joel Iff, Patrick Gagnon‐Sanschagrin, Jerome Bedard et al.
4 links
Rare Kidney Diseases
Renal Diseases and Glomerulopathies
article

Risk of kidney failure across proteinuria levels among patients with immunoglobulin A nephropathy and stable estimated glomerular filtration rate

Manish R. Maski, Joel Iff, Patrick Gagnon‐Sanschagrin, Jerome Bedard, Rajeshwari Nair, Beth Barber, Edward Tuttle, Jiahua Li
article en

Abstract

Abstract Introduction Proteinuria is an established prognostic marker in immunoglobulin A nephropathy (IgAN). Its relevance among patients with stable estimated glomerular filtration rate (eGFR) is less well characterized. This study evaluated patients with stable eGFR to assess if cumulative time-averaged proteinuria (TA-P) is associated with subsequent kidney failure. Methods This retrospective cohort study used linked US claims from Komodo Research Data and electronic medical records (EMR) data from Norstella (2016–2026). Eligible patients were adults aged ≥ 18 years with IgAN identified through diagnosis codes or clinical notes, from claims or EMR. eGFR stability was defined as an annualized slope corresponding to a decline of < 1 mL/min/1.73 m² assessed over 24 (± 6) months. Multivariable Cox proportional hazards models estimated associations between TA-P thresholds and kidney failure, adjusting for demographics, baseline kidney function, comorbidities, hematuria, and treatment use. Results One thousand, two hundred twenty-three patients met the inclusion criteria including having stable eGFR for 2 years. Despite having stable eGFR, patients with TA- P ≥ 0.5 g/day had 1.55 times the hazard of kidney failure compared with patients with TA- P < 0.5 g/day (HR, 1.55; 95% CI, 1.07–2.23; p = 0.019). A similar finding was demonstrated for patients with TA- P ≥ 0.3 g/day versus TA- P < 0.3 g/day (HR, 1.80; 95% CI, 1.21–2.67; p = 0.004). Consistent results were observed across sensitivity analyses including a 1-year stability period. Conclusions Among patients with IgAN and stable eGFR over a 24-month period, achieving the KDIGO-recommended proteinuria targets (< 0.5 g/day, preferably < 0.3 g/day) remains clinically important even when kidney function appears stable.

Rare Kidney DiseasesVol. 1(1)
Vertex Pharmaceuticals (United States) (US), Analysis Group (United States) (US)
Vertex Pharmaceuticals
Good health and well-being
Openalex Percentile: Top 12%
Renal Diseases and Glomerulopathies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon